期刊文献+

HPLC法测定注射用比伐芦定的含量及有关物质 被引量:1

Determination of Content and Related Substances of Bivalirudin for Injection by HPLC
下载PDF
导出
摘要 目的:建立测定注射用比伐芦定含量和有关物质的HPLC方法。方法:方法采用PhenomenexKinetex XB-C18(150 mm×4.6 mm, 2.6μm)色谱柱,以三氟乙酸-水-四氢呋喃-乙腈(2∶800∶100∶100)为流动相,流速0.6 ml·min^(-1),柱温50℃,检测波长210 nm,进样体积10μl。结果:在该色谱条件下,主峰与有关物质均能得到良好分离,主峰和各有关物质在测定的浓度范围内线性关系良好(r值范围0.999 1~1.000 0);比伐芦定和5种有关物质(BIVA((12-20))-BIVA、Plus-Gly-BIVA、Des-Gly-BIVA、Beta-Asp9-BIVA、Alpha-Asp9-BIVA)的检测限分别为0.238 9,0.166 4,0.297 3,0.309 1,0.312 7,0.410 7μg·ml^(-1),平均回收率分别为99.8%,99.6%,99.1%,93.1%,97.5%,102.3%,RSD分别为0.6%,4.1%,2.7%,3.4%,4.3%,1.7%(n=9~12)。结论:该方法重复性好、专属性强,可以更加有效控制注射用比伐芦定的质量。 Objective: To establish an HPLC method for the determination of content and related substances of bivalirudin for injection.Methods: The analytical column was Phenomenex Kinetex XB-C18(150 mm×4.6 mm, 2.6 μm), and the mobile phase consisted of trifluoroacetic acid-water-tetrahydrofuran-acetonitile(2∶800∶100∶100) at the flow rate of 0.6 ml·min^(-1). The column temperature was 50℃ and the detection wavelength was 210 nm. The injection volume was 10 μl. Results: Under above conditions, the main peak and the peaks of the related substances were well separated, and they all had good linear relationships(r=0.999 1-1.000 0). The detection limit of bivalirudin and five related substances(BIVA(12-20)-BIVA, Plus-Gly-BIVA, Des-Gly-BIVA, Beta-Asp~9-BIVA, Alpha-Asp~9-BIVA) was 0.238 9, 0.166 4, 0.297 3, 0.309 1, 0.312 7 and 0.410 7 μg·ml^(-1), respectively;the average recovery was 99.8%, 99.6%, 99.1%, 93.1%, 97.5% and 102.3% with the RSDs of 0.6%, 4.1%, 2.7%, 3.4%, 4.3% and 1.7%(n=9-12), respectively. Conclusion: The method is reproducible and specific, and can effectively control the quality of bivalirudin for injection.
作者 段银 张睿懿 孙继福 李勇 张伟 Duan Yin;Zhang Ruiyi;Sun Jifu;Li Yong;Zhang Wei(Kunming Longjin Pharmaceutical Co.Ltd.,Kunming 650503,China)
出处 《中国药师》 CAS 2022年第12期2255-2259,共5页 China Pharmacist
关键词 高效液相色谱法 注射用比伐芦定 含量 有关物质 HPLC Bivalirudin for injection Content Related substances
  • 相关文献

参考文献8

二级参考文献61

  • 1黄骏雄.HPLC色谱柱性能异常的判别及再生[J].现代仪器使用与维修,1996(2):16-18. 被引量:4
  • 2李俊平,王成福.糖醇高效液相色谱柱的再生[J].天津化工,2007,21(2):49-51. 被引量:2
  • 3刘有芹,颜芸,徐莉,陈明洁.分子印迹聚合物填充色谱柱的研究与发展[J].化学研究与应用,2007,19(4):351-357. 被引量:4
  • 4柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2108
  • 5边素艳,盖鲁粤.直接凝血酶抑制剂比伐卢定临床研究进展[J].中国介入心脏病学杂志,2007,15(3):178-180. 被引量:11
  • 6Bittl JA,Strony J,Brinker JA,et al.Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina.N Engl J Med,1995,333:764-769.
  • 7Bittl JA,Chaitman BR,Feit F,et al.Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina:Final report reanalysis of the Bivalirudin Angioplasty Study.Am Heart J,2001,142:952-959.
  • 8Dangas G,Lasic Z,Mehran R,et al.Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective,multicenter BivAlirudin and Drug-Eluting STents [ADEST] study).Am J Cardiol,2005,96:659-663.
  • 9Rajagopal V,Lincoff AM,Cohen DJ,et al.Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention:an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.Am Heart J,2006,152:149-154.
  • 10Popma JJ,Berger P,Ohman EM,et al.Antithrombotic therapy during percutaneous coronary intervention:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126:576S-599S.

共引文献61

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部